M1

Brigii Launches M1 Handheld Vacuum Cleaner and Receives Attention on Social Media

Retrieved on: 
Wednesday, November 16, 2022

Brigii, based in the Hong Kong is an innovative digital motor technology providing highly efficient cleaning experience

Key Points: 
  • Hong Kong, China--(Newsfile Corp. - November 16, 2022) - The M1 Vacuum Handheld cleaner was launched in 2022 as the newest version of the Brigii handheld vacuum cleaner line.
  • Brigii launched a test marketing campaign for its M1 Vacuum.
  • The M1 Vacuum has received over 25 million views and likes on social media as a result of its open testing.
  • With the motto "Serving all families anytime, anywhere", Brigii started with a handheld vacuum cleaner.

EQS-News: M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market

Retrieved on: 
Sunday, November 27, 2022

M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market

Key Points: 
  • M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market
    Group EBITDA amounts to EUR 10.9 million (previous year: EUR 12.0 million); EBIT amounts to EUR 6.5 million (previous year: EUR 7.8 million)
    Berlin, 14.11.2022 - M1 Kliniken AG (ISIN: DE000A0STSQ8) announces key financial figures for the period Jan - Sep 2022.
  • Accordingly, consolidated group sales for the first nine months amounted to EUR 214 million (previous year: EUR 236 million).
  • With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field.

EQS-News: Expansion of the Management Board of M1 Kliniken AG

Retrieved on: 
Sunday, November 27, 2022

Berlin, 15.11.2022 - At its meeting today, the Supervisory Board of M1 Kliniken AG appointed Mr. Kilian Brenske (28, MBA) to the management board of M1 Kliniken AG.

Key Points: 
  • Berlin, 15.11.2022 - At its meeting today, the Supervisory Board of M1 Kliniken AG appointed Mr. Kilian Brenske (28, MBA) to the management board of M1 Kliniken AG.
  • Mr. Brenske is therefore excellently prepared for his new tasks as the board member responsible for national and international expansion, marketing and purchasing.
  • M1 Kliniken AG is the leading provider of beauty medical health services in Germany.
  • With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field.

EQS-News: MPH Health Care AG: Q3 result 2022

Retrieved on: 
Sunday, November 27, 2022

Berlin, 24 November 2022: MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS result for the third quarter of 2022.

Key Points: 
  • Berlin, 24 November 2022: MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS result for the third quarter of 2022.
  • The IFRS result for the first nine months of the 2022 financial year was EUR -55.8 million (previous year EUR -10.4 million).
  • About MPH Health Care AG:
    MPH Health Care AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market.
  • MPH Health Care AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.

OWC Announces SoftRAID 7 for Mac the Latest Version of the World’s Most Powerful Yet Easy-To-Use RAID Software with Support for macOS 13 Ventura

Retrieved on: 
Monday, November 21, 2022

SoftRAID 7 adds compatibility for Apples latest operating system, macOS 13 Ventura, with support for all Intel and Apple silicon Macs, including M1 and M2 Macs.

Key Points: 
  • SoftRAID 7 adds compatibility for Apples latest operating system, macOS 13 Ventura, with support for all Intel and Apple silicon Macs, including M1 and M2 Macs.
  • SoftRAID 7 underwent a comprehensive, independent deep code review of all components by top macOS security experts to review areas that might be exploited.
  • SoftRAID 7 also includes a free year of our new Upgrade + Support plan, ensuring users always have access to the latest SoftRAID features and maintenance versions.
  • Owners of OWC storage solutions that include SoftRAID XT, may also be eligible for free or upgrade discounts.

M1 Announces High-Yield Savings Account with 4.50% APY

Retrieved on: 
Monday, November 14, 2022

M1 High-Yield Savings Account, available in early 2023, will be an FDIC-insured savings account2.

Key Points: 
  • M1 High-Yield Savings Account, available in early 2023, will be an FDIC-insured savings account2.
  • The base rate for the savings account will be 0.50% APY, and M1 clients with an active M1 Plus membership will earn 4.50% APY.
  • Current and prospective M1 clients can sign up for more information on the M1 High-Yield Savings Account directly on M1.com starting November 14, 2022.
  • The M1 High-Yield Savings Account is the latest addition to our automated, integrated and expanding offering, said Brian Barnes, M1 CEO and Founder.

Qudian Inc. Reports Third Quarter 2022 Unaudited Financial Results

Retrieved on: 
Monday, November 21, 2022

XIAMEN, China, Nov. 21, 2022 /PRNewswire/ -- Qudian Inc. ("Qudian" or "the Company" or "We") (NYSE: QD), a consumer-oriented technology company inChina, today announced its unaudited financial results for the quarter ended September 30, 2022.

Key Points: 
  • XIAMEN, China, Nov. 21, 2022 /PRNewswire/ -- Qudian Inc. ("Qudian" or "the Company" or "We") (NYSE: QD), a consumer-oriented technology company inChina, today announced its unaudited financial results for the quarter ended September 30, 2022.
  • Total operating costs and expenses increased to RMB410.6 million (US$57.7 million) from RMB273.2 million for the third quarter of 2021.
  • Impairment loss from long-lived assets was RMB5.9 million(US$0.8 million) for the third quarter of 2022, as a result of thestreamlining in QD Food operations.
  • We use adjusted net income/loss, a Non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes.

Aidoc Secures New FDA Clearances Enabling Faster and More Accurate Detection of Critical Neurological and Cardiovascular Conditions

Retrieved on: 
Thursday, November 17, 2022

NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Aidoc, the leading provider of healthcare AI solutions, today announced it has increased its FDA clearances to 11 with the addition of CT-based AI solutions - aortic dissection (AD) and all vessel occlusions (VOs). These clearances continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.

Key Points: 
  • These clearances continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.
  • "Effective healthcare and treatment of acute conditions, like stroke and aortic dissections, require rapid, coordinated care minutes can matter," said Aidoc CEO Elad Walach.
  • Aidoc is the only company with a proven EHR integration for the population of critical, time-sensitive patient information on the app.
  • Aidoc is the leading provider of artificial intelligence healthcare solutions that empower physicians to expedite patient treatment and enhance quality of care.

Egnyte Strengthens Secure File Sharing Platform, Providing Customers with Enhanced User Experience

Retrieved on: 
Tuesday, November 15, 2022

MOUNTAIN VIEW, Calif., Nov. 15, 2022 /PRNewswire-PRWeb/ -- Egnyte, the secure platform for content collaboration and governance, announced several product enhancements that will improve the overall user experience by strengthening security controls, improving productivity, and ensuring better operations across the business. Based on customer feedback and market trends, the updates include enhancements to the web user interface (UI) through the ongoing redesign including improved readability for a best-in-class user experience (UX) and simpler, more efficient ransomware recovery features to quickly bounce back from a cyberattack.

Key Points: 
  • "Egnyte is dedicated to giving our customers an easier way to conduct their business in one of the safest environments possible," said Ramin Farassat, chief product officer at Egnyte.
  • "Our latest enhancements are a result of our product, engineering, and sales teams listening to our customers to enhance the overall experience in our platform.
  • Major updates to the Egnyte platform within the last quarter include:
    Egnyte Web UI Redesign: This is an ongoing project as part of Egnyte's commitment to delivering a best-in-class user experience to its customers.
  • Egnyte Desktop App Core: Built on Apple's new File Provider framework, the Desktop App Core is easy to deploy on M1 and M2-based Macs.

Avstera Therapeutics Receives FDA Orphan Drug Designation on AVS100 for Treatment of Advanced Stage Melanoma

Retrieved on: 
Friday, November 11, 2022

PHILADELPHIA, Nov. 11, 2022 /PRNewswire/ -- Avstera Therapeutics Corp, an oncology-focused biotech dedicated to address the large disease burden and significant unmet need of cancer patients, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avstera's AVS100 compound, which is a highly specific HDAC6 inhibitor, for the treatment of stage IIB through IV melanoma. 

Key Points: 
  • AVS100 is a novel highly specific HDAC6 inhibitor with unique mechanisms in its ability to polarize macrophages to the anti-tumoral M1 phenotype.
  • AVS100 has been shown to significantly reduce tumor growth and improve overall survival in preclinical animal models.
  • AVS100 remains on track for planned IND filing next year targeting locally advanced or metastatic solid tumors, including melanoma.
  • Advanced stage melanoma remains a complex and difficult cancer to treat with current approaches, and AVS100 has the potential to provide an opportunity to potentially reduce the disease burden shared by these patients."